PCSK9 inhibition: an important step forward in treating dyslipidemia in high-risk patients

Event: ESC CONGRESS 2015
Topic: Lipids
Session type: Satellite Symposium
Sponsored by Amgen
Date: 1 September 2015
Time: 12:45 - 13:45

4 presentations in this session

Welcome and introduction - PCSK9 inhibition: an important step forward in treating dyslipidemia in high-risk patients.

Speaker: Professor E. Stroes (Amsterdam, NL)
Thumbnail

PCSK9 inhibition: the road to effective management of high-risk patients.

Speaker: Professor J. Chapman (Paris, FR)
Thumbnail

Paving the way to a better future for high-risk patients.

Speaker: Professor K. Ray (London, GB)
Thumbnail

Closing remarks - PCSK9 inhibition: an important step forward in treating dyslipidemia in high-risk patients.

Speaker: Professor E. Stroes (Amsterdam, NL)
Thumbnail

4 speakers from this session

Professor Erik Stroes

Academic Medical Centre, Amsterdam (Netherlands (The))
24 presentations
0 follower

Professor John Chapman

Medical Faculty, Sorbonne University, Pitie-Salpetriere University hospital, Paris (France)
15 presentations
0 follower

Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)
59 presentations
3 followers

Professor Erik Stroes

Academic Medical Centre, Amsterdam (Netherlands (The))
24 presentations
0 follower

This platform is supported by

logo Novo Nordisk